FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
How Medicare Part D Has Changed for 2025
Medicare has undergone several major changes since it launched in 1965. And now, with the passage of the Inflation Reduction Act of 2022, it's poised to change again, with several key ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Winston-Salem Journal6d
Medicare selects 15 prescription drugs for second negotiating round
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
Health Affairs8d
Medicare Reforms Necessitate More Formulary Oversight
Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish ...
ohiocapitaljournal8d
Unions file suit against drug middlemen, insulin makers on behalf of thousands, Ohio, elsewhere
Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...
Trump Order Walks Back Biden-Era Effort To Lower Prescription Drug Prices. Here's Context
Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid ...
Managed Healthcare Executive9d
Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and ...
MM&M9d
Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...